An international team of investigators created a clinical decision support tool to assist in identifying patients with ulcerative colitis most likely to benefit from treatment with vedolizumab.
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
A team of investigators sought to determine the influence of infliximab on gut bacterial and fungal composition in patients with inflammatory bowel disease.
As Crohn disease perianal fistulas often do not respond to available treatments, researchers developed a patient-derived quality-of-life tool to evaluate the impact of the condition on patients.
A team of investigators studied a group of asymptomatic patients who were at increased risk of developing inflammatory bowel disease to assess proteolytic activity in advance of a diagnosis of ulcerative colitis.
A team of researchers from the Mayo Clinic aimed to assess survival among patients with rectal cancer with or without inflammatory bowel disease.
The immune-related AE, immune-mediated diarrhea and colitis, can have a limited course or may exist for long-term periods.
Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.
Lower socioeconomic status is associated with worse outcomes for inflammatory bowel disease.
Thromboembolic disease risk in people with inflammatory bowel disease may be influenced by patient genetics, including polygenic risk scores.
